Analytical Characterization and Stability Assessment of RNA-Based Vaccines
Authors:
- Hadi M. AlasmariHAHadi M. Alasmari
- Shouq F. AlghannamSAShouq F. Alghannam
- Hassan A. Al-MoammarHAHassan A. Al-Moammar
- Dimah K. AlrabiahDADimah K. Alrabiah
- Seham S. Al-HarthySASeham S. Al-Harthy
- Essam J. AlyamaniEAEssam J. Alyamani
- Sami A. AlyahyaSASami A. Alyahya
- Mohammad AlkhrayefMAMohammad Alkhrayef
- Mohannad FallatahMFMohannad Fallatah
- Samiyah Al-KhaldiSASamiyah Al-Khaldi
- Abdulmalek T. AlgarniAAAbdulmalek T. Algarni
- Yahya F. JamousYahya F. Jamous
Open Access
- 27 June 2026
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (7) , 790
Abstract
Ribonucleic acid-based vaccines have emerged as one of the most significant advances in modern vaccine development, demonstrating remarkable clinical success and enabling rapid responses to emerging infectious diseases. Despite their therapeutic potential, the development of these vaccines remains challenging because of the inherent instability of ribonucleic acid molecules, their susceptibility to degradation, and the complexity of formulation design. Ensuring product quality, stability, and biological performance therefore requires comprehensive analytical characterization throughout development, manufacturing, storage, and quality control. This review provides a comprehensive overview of current analytical strategies used to evaluate ribonucleic acid-based vaccine formulations. Key analytical approaches for assessing molecular integrity, purity, encapsulation efficiency, particle morphology, size distribution, surface characteristics, structural attributes, and biological potency are discussed. The review also examines the influence of formulation composition, lipid nanoparticle design, manufacturing processes, and storage conditions on vaccine stability and performance. In addition, major degradation pathways, critical quality attributes, and analytical challenges associated with quality assessment are highlighted. Furthermore, current regulatory considerations and limitations of existing analytical methodologies are discussed, particularly the challenges associated with establishing robust relationships between physicochemical properties and biological efficacy. The review emphasizes the importance of integrated multi-method analytical approaches for comprehensive characterization and quality assurance. Continued advances in analytical technologies and standardization efforts will be essential for supporting the development of safe, effective, and stable ribonucleic acid-based vaccines and for facilitating their broader pharmaceutical applications.Keywords
This publication has 207 references indexed in Scilit:
- Concentration Approaches for mRNA and mRNA–LNP Formulations: Enabling mRNA Integrity Quantification in Low‐Concentration FormulationsElectrophoresis, 2026
- Process and analytical strategies for the safe production of mRNA vaccines and therapeuticsMolecular Biology Reports, 2026
- PRELIVE: A Framework for Predicting Lipid Nanoparticles In Vivo Efficacy and Reducing Reliance on Animal TestingAdvanced Functional Materials, 2025
- A Comprehensive Lateral Flow Strip Assay for On‐Site mRNA Vaccine Quality Control in Decentralized ManufacturingAdvanced Science, 2025
- Current PAT Landscape in the Downstream Processing of BiopharmaceuticalsAnalytical Science Advances, 2025
- Development of an advanced separation and characterization platform for mRNA and lipid nanoparticles using multi-detector asymmetrical flow field-flow fractionationAnalytical and Bioanalytical Chemistry, 2024
- Toward an international standardisation roadmap for nanomedicineDrug Delivery and Translational Research, 2024
- Safety Monitoring of COVID‐19 Vaccines: Perspective from the European Medicines AgencyClinical Pharmacology & Therapeutics, 2023
- Two quality and stability indicating imaged CIEF methods for mRNA vaccinesElectrophoresis, 2022
- Induction of virus‐specific cytotoxic T lymphocytes in vivo by liposome‐entrapped mRNAEuropean Journal of Immunology, 1993